TrialsgrambetaRCTs are beautiful

Chronic kidney disease & progression

RAAS blockade, SGLT2 inhibitors, finerenone, GLP-1 agonists and blood-pressure targets.

Trials
14
Years
1993–2024
Sort
  • 2024FLOW Core⁠GLP-1 RAIn 3,533 patients with type 2 diabetes and CKD, semaglutide reduced the composite of kidney failure, ≥50% eGFR decline or renal/CV death compared with placebo.HR 0.7695% CI 0.66-0.88Read →
  • 2023EMPA-KIDNEY⁠SGLT2 inhibitorsIn 6,609 patients across a broad spectrum of CKD, empagliflozin reduced kidney-disease progression or cardiovascular death compared with placebo.HR 0.7295% CI 0.64-0.82Read →
  • 2021FIGARO-DKD⁠Nonsteroidal MRAIn 7,437 patients with type 2 diabetes and CKD, finerenone reduced the cardiovascular composite compared with placebo.HR 0.8795% CI 0.76-0.98Read →
  • 2020DAPA-CKD Core⁠SGLT2 inhibitorsIn 4,304 patients with CKD with or without diabetes, dapagliflozin reduced the composite of ≥50% eGFR decline, ESKD or renal/CV death compared with placebo.HR 0.6195% CI 0.51-0.72Read →
  • 2020FIDELIO-DKD Core⁠Nonsteroidal MRAIn 5,734 patients with type 2 diabetes and CKD, finerenone reduced the composite of kidney failure, ≥40% eGFR decline or renal death compared with placebo.HR 0.8295% CI 0.73-0.93Read →
  • 2019CREDENCE Core⁠SGLT2 inhibitorsIn 4,401 patients with type 2 diabetes and albuminuric CKD on maximal RAS blockade, canagliflozin reduced the composite of ESKD, creatinine doubling or renal/CV death compared with placebo.HR 0.7095% CI 0.59-0.82Read →
  • 2019SONAR⁠Endothelin antagonistsIn 2,648 patients with type 2 diabetes and CKD selected for response, atrasentan reduced the composite of creatinine doubling or ESKD compared with placebo.HR 0.6595% CI 0.49-0.88Read →
  • 2017SPRINT-CKD⁠Blood-pressure targetsIn 2,646 participants with chronic kidney disease, an intensive systolic-BP target below 120 mmHg reduced all-cause mortality compared with a target below 140 mmHg.HR 0.72CI 0.53-0.99Read →
  • 2013VA NEPHRON-D⁠RAAS blockadeIn 1,448 patients with type 2 diabetes and albuminuric CKD, dual blockade with losartan plus lisinopril did not reduce the renal composite compared with losartan alone.HR 0.8895% CI 0.70-1.12Read →
  • 2002AASK⁠RAAS blockadeIn 1,094 Black patients with hypertensive nephrosclerosis, ramipril slowed kidney-disease progression compared with amlodipine or metoprolol.Read →
  • 2001RENAAL Core⁠RAAS blockadeIn 1,513 patients with type 2 diabetes and nephropathy, losartan reduced the composite of creatinine doubling, ESRD or death compared with placebo.Read →
  • 2001IDNT Core⁠RAAS blockadeIn 1,715 patients with type 2 diabetes and nephropathy, irbesartan reduced progression of the renal composite compared with amlodipine or placebo.Read →
  • 1997REIN⁠RAAS blockadeIn 352 patients with non-diabetic proteinuric chronic kidney disease, ramipril slowed GFR decline and progression to ESRD compared with placebo.Read →
  • 1993Captopril-DN Core⁠RAAS blockadeIn 409 patients with type 1 diabetes and diabetic nephropathy, captopril reduced doubling of serum creatinine compared with placebo.HR 0.5295% CI 0.31-0.84Read →